Several anti-inflammatory and urate-lowering drugs used in gout have been found to have a favorable effect on cardiovascular (CV) outcomes.

Colchicine is first-line therapy in both gout and pericarditis. It has also demonstrated benefit in the prevention of ischemic events in patients with stable coronary artery disease (CAD) and recent myocardial infarction (MI), postpericardiotomy syndrome and postoperative atrial fibrillation.

Allopurinol may have a potential cardioprotective effect, particularly in the reduction of blood pressure and prevention of MI.

CV outcomes with febuxostat are non-inferior to allopurinol and the long-term use of febuxostat is not associated with increased death or CV mortality.

The CV effects of newer gout drugs such as arhalofenate, verinurad, and rilonacept need to be evaluated.